ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2017
A randomized, open-label assessor blinded, multi-center, controlled phase III Trial to evaluate the efficacy of AOP2014 administered bi-weekly subcutaneously (s.c.) in preventing molecular relapse (loss of MMR) in CML patients, who discontinue ABL tyrosine kinase inhibitor therapy (TKI) in deep molecular remission of MR4 or better (MR4.5, or MR5).
Epistemonikos ID: 6612963339670d86c04fbe60ebade18c0963dd16
First added on: Jan 21, 2022